Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Liposomal Mitoxantrone in R/R PTCL and NK/T-cell Lymphoma
NCT03776279Phase 2Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Apr 2018
- Primary completion
- Dec 2020
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma (PTCL), Natural killer T-cell lymphoma (NKTL), sponsored by CSPC ZhongQi Pharmaceutical Technology. Status: unknown.
02
Drugs
mitoxantrone hydrochloride liposome
03
Conditions
peripheral T-cell lymphoma (PTCL)Natural killer T-cell lymphoma (NKTL)
Beyond the preview
Go deeper on NCT03776279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03776279.